CPCarlos Paván

Carlos Paván

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Paván has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Alejandro Daniel Nadra

    Departamento de Química Biológica Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, IQUIBICEN-CONICET, Buenos Aires, Argentina

    2 shared publications
  • Cecilia D Alessio

    Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Instituto de Biociencias, Biotecnología y Biología Traslacional, Ciudad Autónoma de Buenos Aires, Argentina

    2 shared publications
  • Diana E. Wetzler

    Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales Universidad de Buenos Aires (FCEN‐UBA) Ciudad de Buenos Aires Argentina

    2 shared publications
  • Ernesto A. Roman

    Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN). Intendente Güiraldes 2160 - Ciudad Universitaria, 1428EGA C.A.B.A., Argentina

    2 shared publications
  • Hernán Gentilli

    Department of Physiology and Molecular and Cellular Biology, Institute of Biosciences, Biotechnology and Translational Biology (iB3), Faculty of Exact and Natural Sciences, University of Buenos Aires, Intendente Güiraldes 2160, Buenos Aires C1428EG, Argentina

    2 shared publications
  • Javier Santos

    Instituto de Biociencias, Biotecnología y Biología Traslacional (iB3), Universidad de Buenos Aires, Buenos Aires, Argentina

    2 shared publications

Latest Publications

  • Open Access

    Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain Using Pichia pastoris in Stirred-Tank Bioreactor

    by Diego G. Noseda, Cecilia D’alessio, Javier Santos, Tommy Idrovo-Hidalgo, Florencia Pignataro, Diana E. Wetzler, Hernán Gentili, Alejandro D. Nadra, Ernesto Roman, Carlos Paván, et al.

    SARS-CoV-2 was identified as the pathogenic agent causing the COVID-19 pandemic. Among the proteins codified by this virus, the Spike protein is one of the most-external and -exposed. A fragment of the Spike protein, named the receptor binding domain (RBD), interacts with the ACE2 receptors of human cells, allowing the entrance of the viruses. RBD has been proposed as an interesting protein for the development of diagnosis tools, treatment, and prevention of the disease. In this work, a method for recombinant RBD production using Pichia pastoris as a cell factory in a stirred-tank bioreactor (SRTB) up to 7 L was developed. Using a basal saline medium with glycerol, methanol, and compressed air in a four-stage procedure, around 500 mg/L of the raw RBD produced by yeasts (yRBD) and 206 mg/L of purified (>95%) RBD were obtained. Thereby, the proposed method represents a feasible, simple, scalable, and inexpensive procedure for the obtention of RBD for diagnosis kits and vaccines’ formulation.


  • Open Access

    Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain (RBD) Using Pichia pastoris in Stirred-Tank Bioreactor

    by Diego Noseda, Cecilia D’Alessio, Javier Santos, Tommy Idrovo-Hidalgo, Maria Florencia Pignataro, Diana E Wetzler, Hernán Gentilli, Alejandro D Nadra, Ernesto Roman, Carlos Paván, et al.

    SARS-CoV-2 was identified as the pathogenic agent causing the COVID-19 pandemic. Among the proteins codified by this virus, the Spike is one of the most external and exposed. A fragment of the Spike protein, named the Receptor Binding Protein (RBD) interacts with the ACE2 receptors of human cells, allowing the entrance of the viruses. RBD has been proposed as an interesting protein for the development of diagnosis tools, treatment and prevention of the disease. In this work, a method for recombinant RBD production using Pichia pastoris as a cell factory in a Stirred Tank Bioreactor (SRTB) up to 7 L was developed. Using a basal saline medium with glycerol, methanol and compressed air in a four stages procedure, around 500 mg/L of raw yRBD (RBD produced by yeasts) and 206 mg/L of purified (>95%) RBD were obtained. Thereby, the proposed method represents a feasible, simple, scalable and cheap procedure for the obtention of RBD for diagnosis kits and vaccines formulation